- Home
- NFJ vs PHVS Comparison
NFJ vs PHVS Comparison
Compare NFJ & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- PHVS
- Stock Information
- Founded
- NFJ 2005
- PHVS 2015
- Country
- NFJ United States
- PHVS Netherlands
- Employees
- NFJ N/A
- PHVS N/A
- Industry
- NFJ Finance: Consumer Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- PHVS Health Care
- Exchange
- NFJ Nasdaq
- PHVS Nasdaq
- Market Cap
- NFJ 1.3B
- PHVS 1.0B
- IPO Year
- NFJ N/A
- PHVS 2021
- Fundamental
- Price
- NFJ $12.30
- PHVS $19.57
- Analyst Decision
- NFJ
- PHVS Strong Buy
- Analyst Count
- NFJ 0
- PHVS 5
- Target Price
- NFJ N/A
- PHVS $40.60
- AVG Volume (30 Days)
- NFJ 223.5K
- PHVS 110.9K
- Earning Date
- NFJ 01-01-0001
- PHVS 11-13-2024
- Dividend Yield
- NFJ 9.01%
- PHVS N/A
- EPS Growth
- NFJ N/A
- PHVS N/A
- EPS
- NFJ N/A
- PHVS N/A
- Revenue
- NFJ N/A
- PHVS N/A
- Revenue This Year
- NFJ N/A
- PHVS N/A
- Revenue Next Year
- NFJ N/A
- PHVS N/A
- P/E Ratio
- NFJ N/A
- PHVS N/A
- Revenue Growth
- NFJ N/A
- PHVS N/A
- 52 Week Low
- NFJ $10.45
- PHVS $15.37
- 52 Week High
- NFJ $12.86
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- NFJ 28.81
- PHVS 47.85
- Support Level
- NFJ $12.15
- PHVS $18.01
- Resistance Level
- NFJ $13.30
- PHVS $20.17
- Average True Range (ATR)
- NFJ 0.14
- PHVS 1.33
- MACD
- NFJ -0.11
- PHVS 0.01
- Stochastic Oscillator
- NFJ 12.61
- PHVS 56.45
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. Its primary investment objective is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .